Lung Rejuvenation ACT: What It Means for COPD and Chronic Lung Disease | ALIV

ALIV's Lung Rejuvenation ACT programme — positioned under the tagline "Breathing Life into Your Future" — reflects the clinic's application of autologous cell therapy to chronic pulmonary conditions where the standard management ceiling has been reached. The programme is most relevant for COPD, but the principles extend to other chronic inflammatory lung conditions where the paracrine anti-inflammatory and regenerative mechanism of ACT offers clinical value. This article provides a deeper look at the pulmonary application beyond the introductory COPD article.

Beyond Inhalers: What ACT Addresses That Medication Cannot

Inhaled bronchodilators and corticosteroids produce their clinical benefit by relaxing airway smooth muscle and reducing airway inflammation directly — they are effective and essential, but their mechanism is symptomatic and temporary, not regenerative. Each dose of bronchodilator relaxes the airways for hours; between doses, the underlying inflammatory environment returns to its baseline. Inhaled corticosteroids reduce airway inflammation while taken, but do not reverse the alveolar destruction and small airway remodelling that have already occurred. ACT, delivered systemically, aims to shift the chronic inflammatory microenvironment of the COPD lung toward a less destructive state — not through temporary pharmacological suppression but through sustained paracrine modulation of the chronic neutrophilic and macrophage-driven inflammation. The effect persists while the paracrine signals remain active and their downstream cellular changes are maintained.

Additionally, ACT's VEGF-driven angiogenic effect has a pulmonary specific relevance: pulmonary vascular remodelling is a component of COPD pathology — reduced capillary density in emphysematous lung tissue reduces the gas exchange surface available for oxygen uptake. VEGF stimulation of pulmonary angiogenesis represents a mechanistic attempt to restore some of this vascular capacity. Whether this produces measurable gas exchange improvement — measured by DLCO (diffusing capacity) — in the clinical setting is one of the monitoring parameters ALIV tracks in its COPD ACT patients at six months. See: ACT for COPD — the clinical introduction.

Functional Improvement Targets

The clinical goals in ALIV's lung ACT programme: six-minute walk distance improvement (a validated functional outcome measure for COPD); St. George's Respiratory Questionnaire (SGRQ) quality of life score improvement; reduction in COPD exacerbation frequency; and improved MRC dyspnoea scale score. Spirometric improvement (FEV1, FVC) is a secondary goal — spirometric changes in COPD from non-surgical interventions are typically modest; functional and quality of life improvements often precede spirometric changes. Response is variable and condition-stage dependent.

Is smoking cessation required before lung ACT?

Absolutely and non-negotiably — active smoking is an exclusion criterion for ALIV's lung ACT programme. The ongoing oxidative, inflammatory injury from cigarette smoke directly opposes the anti-inflammatory paracrine support of ACT, and the growth factors delivered would be working against a continuing destructive stimulus. ALIV will not offer lung ACT to patients who are actively smoking. For patients who are in the process of cessation, a minimum of three months of confirmed abstinence before the procedure is the clinical standard. ALIV's clinical team can provide referral guidance for smoking cessation support as a prerequisite to ACT consideration.

Can ACT help with breathlessness from non-COPD lung conditions?

The anti-inflammatory paracrine mechanism of ACT has mechanistic relevance for any chronic inflammatory pulmonary condition — including chronic asthma with fixed airflow obstruction, bronchiectasis with chronic inflammatory burden, and interstitial lung disease (ILD) where inflammation drives progressive fibrosis. The clinical evidence for ACT in non-COPD lung conditions is more limited than for COPD, and each condition requires individual assessment of whether the mechanism-treatment alignment justifies the procedure. Patients with non-COPD lung conditions should raise this explicitly at the pre-ACT consultation.